GlassScriptPhysician profile
David A Dicecco
NPI 1831201839
$7,090.39
in general payments reported to CMS, 2019-2025
48 companies · $1,930 in 2025
The $1,930 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $416 · 2021: $1,158 · 2022: $845 · 2023: $1,038 · 2024: $1,117 · 2025: $1,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,084.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $767.73 | 2019-2025 | Tezspire, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $703.30 | 2020-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $689.61 | 2019-2024 | Xarelto |
| Mylan Specialty L.P. | $603.58 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $485.79 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $370.80 | 2024-2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $365.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $347.01 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $234.46 | 2021-2024 | Hetlioz, Fanapt |
| Astellas Pharma US INC | $185.66 | 2019-2024 | Cresemba |
| Baxter Healthcare | $182.44 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Exact Sciences Corporation | $177.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Verona Pharma, INC. | $152.09 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $130.26 | 2021-2023 | |
| Lundbeck LLC | $124.92 | 2024-2025 | Rexulti |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $119.73 | 2025 | Zerbaxa |
| Philips North America LLC | $115.89 | 2022-2025 | Vest Therapy Und, (O58) Sleep Respiratory Care Und, (Ak6) Vest Therapy |
| Mallinckrodt Hospital Products INC. | $111.97 | 2025 | Acthar |
| Abbott Laboratories | $108.75 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $97.87 | 2023-2025 | Repatha, Tezspire |
| Inogen, INC. | $83.55 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $80.94 | 2025 | Rexulti |
| Ani Pharmaceuticals, INC. | $66.36 | 2025 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $64.34 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $56.37 | 2025 | Opsumit, Uptravi |
| Abbvie INC. | $46.53 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $45.84 | 2019 | |
| Lilly USA, LLC | $45.55 | 2021-2024 | Mounjaro, Zepbound |
| Covis Pharma Gmbh | $43.06 | 2021 | |
| Viiv Healthcare Company | $42.50 | 2020-2025 | Dovato |
| Genzyme Corporation | $39.23 | 2023 | |
| Amarin Pharma, INC. | $35.97 | 2021 | |
| Paratek Pharmaceuticals, INC. | $35.10 | 2023-2025 | Nuzyra |
| Ultragenyx Pharmaceutical INC. | $34.65 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $33.49 | 2021 | |
| Melinta Therapeutics, LLC | $31.84 | 2019 | |
| 3b Medical, INC. | $25.97 | 2025 | Luna |
| Kyowa Kirin, INC. | $23.16 | 2020 | |
| Axsome Therapeutics, INC. | $22.91 | 2025 | Sunosi |
| E.R. Squibb & Sons, L.L.C. | $22.02 | 2020 | |
| Insmed, INC. | $19.63 | 2025 | Arikayce |
| Shield Therapeutics INC | $19.41 | 2024 | |
| Lucid Diagnostics INC. | $19.19 | 2024 | |
| Alnylam Pharmaceuticals INC. | $18.77 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $17.95 | 2024 | |
| Scilex Pharmaceuticals INC. | $15.66 | 2023 | Ztlido |
| Medicomp INC | $13.51 | 2025 | Telepatch Cardiac Monitor |
| Gilead Sciences, INC. | $12.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dicecco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.